Drug Discovery

The medical community is currently witnessing a profound shift in how we approach the most aggressive childhood cancers, moving away from the blunt force of radiation toward the elegant precision of molecular reprogramming. Rhabdomyosarcoma, or RMS, remains a high-stakes challenge in pediatric

The pharmaceutical landscape often operates on a razor's edge where multi-billion dollar investments can be validated or neutralized by a single data readout from a Phase 3 clinical trial. Merck and Gilead Sciences currently find themselves navigating this volatility as they balance the demands of

Ivan Kairatov is a seasoned veteran in biopharmaceutical research and development, having spent nearly two decades navigating the complex intersection of molecular biology and clinical strategy. With a deep specialization in small molecule innovation and a career dedicated to the evolution of

The clinical landscape for treating advanced head and neck cancers has undergone a radical transformation following the publication of results from the Phase Ib/II OrigAMI-4 clinical trial, which offers a lifeline to those facing terminal diagnoses. This pivotal study, spearheaded by investigators

The diagnosis of metastatic cancer often carries a heavy burden of finality, where the primary objective of medical intervention shifts almost exclusively toward palliative care and the management of inevitable decline. For decades, patients grappling with the spread of malignancy to their skeletal

The landscape of neuro-pediatrics shifted significantly when medical professionals successfully administered a groundbreaking gene replacement therapy to an infant suffering from a rare, terminal genetic condition. This procedure, performed at the Schneider Children's Medical Center, targeted